RA
DRNA

Royce & Associates’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Royce & Associates’s Portfolio DRNA Stock Details DRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-1,854
Closed -$47K – 1201
2020
Q2 		$47K Buy
+1,854
New +$39.9K ﹤0.01% 1042

Other funds holding DRNA

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Royce & Associates's DRNA Position: Q3 2020 in Review

Royce & Associates sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q3 2020, closing a stake of 1,854 shares — an estimated $47K sold.

Royce & Associates first reported a position in DRNA in Q2 2020 and held it in 1 quarter. The position peaked at $47K in Q2 2020. 172 funds tracked by Wall St. Rank hold DRNA as of Q3 2020.

  • Royce & Associates reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
  • Royce & Associates sold 1,854 Dicerna Pharmaceuticals, Inc. shares in Q3 2020, an estimated $47K.
  • Royce & Associates first reported a position in Dicerna Pharmaceuticals, Inc. in Q2 2020 and held it in 1 quarter.
  • Royce & Associates's Dicerna Pharmaceuticals, Inc. position peaked at $47K in Q2 2020.
  • 172 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q3 2020.

Based on Royce & Associates's 13F filing for Q3 2020, filed 12 Nov 2020.